Entero Therapeutics, Inc. announced a 1 for 3 reverse stock split of its common stock.
The reverse stock split is aimed at regaining compliance with the Nasdaq listing requirements.
The Company's common stock is expected to trade on a split-adjusted basis starting from August 18, 2025.
Reverse Stock Split
A 1 for 3 reverse stock split will reduce outstanding shares from 4.77 million to 1.59 million.
Board Approval
The reverse split was approved by the Board of Directors and shareholders.
Compliance Aim
The split is part of a plan to meet Nasdaq's minimum bid price requirement.
- The reverse stock split aims to enhance shareholder value and credibility through a Nasdaq listing.
- The split will facilitate compliance with Nasdaq Listing Rule 5550(a)(2) regarding minimum bid price.
The reverse stock split marks a strategic move by Entero Therapeutics to align with Nasdaq requirements and strengthen its position in the market.